We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 9 of 64 for:    lyme

Sofia 2 Lyme FIA Whole Blood Clinical Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03238274
Recruitment Status : Recruiting
First Posted : August 3, 2017
Last Update Posted : September 11, 2017
Sponsor:
Information provided by (Responsible Party):

August 1, 2017
August 3, 2017
September 11, 2017
June 6, 2017
October 2017   (Final data collection date for primary outcome measure)
Detection of anti-B. burgdorferi IgG / IgM antibody [ Time Frame: 15 minutes ]
Accurate detection of presence or absence of anti-B. burgdorferi IgG / IgM antibody
Same as current
Complete list of historical versions of study NCT03238274 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Sofia 2 Lyme FIA Whole Blood Clinical Study
Sofia 2 Lyme FIA Whole Blood Clinical Study
The objective of this study is to demonstrate the clinical performance of the Sofia® 2 analyzer and Sofia Lyme FIA test in the CLIA waived test environment in comparison to Comparator Method(s) and/or an FDA cleared predicate test(s) using matched finger-stick, whole blood and serum from symptomatic subjects.
The objective of this study is to demonstrate the clinical performance of the Sofia® 2 analyzer and Sofia Lyme FIA test in the CLIA waived test environment in comparison to Comparator Method(s) and/or an FDA cleared predicate test(s) using matched finger-stick, whole blood and serum from symptomatic subjects. The finger-stick and venous whole blood specimens will be tested by CLIA waived test operators. The matched plasma (from the leftover whole blood) and serum specimens will be sent to a separate reference laboratory for testing to compare the matched specimen using the Comparator Method(s) and/or an FDA-cleared predicate test(s). The results of this study may be used to support a 510(k) and/or CLIA-Waiver submission for testing whole blood sample types.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Known or suspected exposure or tick-bite from an endemic area prior to onset of symptoms
Borrelia; Infection, Burgdorferi (Erythema Chronicum Migrans)
Device: Sofia 2 Lyme FIA testing
IVD testing of whole blood or serum/plasma to aid in the detection of anti-B. burgdorferi IgG / IgM antibody
  • Arm 1
    Arm 1 is a multi-site, single visit, prospective clinical study where subjects will be enrolled based on a physician's assessment of current Lyme specific symptoms from recent contact with a tick.
    Intervention: Device: Sofia 2 Lyme FIA testing
  • Arm 2
    Arm 2 will consist of subjects selected from a pool of patients that were previously determined to have Lyme disease either by the presence of the diagnostic rash (erythema migrans) or through laboratory findings and physician diagnosis based on patient symptoms. In this Arm the site may recruit by contacting subjects previously diagnosed with Lyme disease no longer than 16 months post diagnosis and no earlier than 1 week post diagnosis.
    Intervention: Device: Sofia 2 Lyme FIA testing
  • Arm 3
    Arm 3 will consist of subjects selected from a pool of patients that were previously determined to have Lyme disease either by the presence of the diagnostic rash (erythema migrans) or through laboratory findings and physician diagnosis based on patient symptoms. In this Arm the site may recruit by contacting subjects previously diagnosed with Lyme disease between 17 months and 50 months post diagnosis. For the subject to be enrolled, a physician must have diagnosed the subject to have Lyme disease based on clinical symptoms.
    Intervention: Device: Sofia 2 Lyme FIA testing
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1800
October 2017
October 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Arm 1 - Prospective symptomatic subjects, must have had a known or suspected exposure or tick-bite from an endemic area prior to onset of symptoms, and be currently exhibiting the following:
  • The physician determines that the subject has an expanding erythema migrans (EM) lesion or "bulls-eye rash" with evidence of clearing in the center and has requested 2 tier serological testing or prescribed a ≥10 day course of antibiotics such as doxycycline in subjects > 8 years old or amoxicillin, cefuroxime or doxycycline in subjects ≤8 years of age:

Or

- The physician must observe current symptoms, including:

At least three (3) of the listed acute stage symptoms listed:

  • fatigue
  • night sweats
  • chills
  • fever
  • headache
  • arthralgia
  • mildly stiff neck
  • myalgia i. one or more symptoms a. through h. are determined to be intermittent

Or,

  • at least one (1) of the following current conditions:
  • recurrent, brief attacks (weeks/months) of objective joint swelling in one or more joints, sometimes followed by chronic arthritis in one or a few joints,
  • lymphocytic meningitis
  • cranial neuritis (partial facial palsy and may be bilateral)
  • radiculoneuropathy
  • encephalomyelitis
  • acute onset of high-grade (2nd or 3rd degree) atrioventricular conduction defects that resolve in days to weeks, sometimes associated with myocarditis

In addition, the physician must be sufficiently confident in the possibility of Lyme disease to have requested two-tier diagnostic testing and/or prescribed a ≥10 day course of antibiotics such as doxycycline in patients > 8 years old or amoxicillin, cefuroxime or doxycycline in patients ≤8 years of age.

Arm 2 - Previously diagnosed with Lyme disease / confirmed case of Lyme disease: Within the past 16 months, a physician must have previously diagnosed the subject based on the presence of an EM rash or based on symptoms and confirmed by laboratory findings as outlined in the CDC two Tier Testing algorithm. A copy of the subject's medical record documenting the diagnosis must be obtained, and kept as source documentation at the enrolling site.

Arm 3 - Previously diagnosed with Lyme disease / confirmed case of Lyme disease: Within the past 17 to 50 months, a physician must have previously diagnosed the subject based on the presence of an EM rash or based on symptoms and confirmed by laboratory findings as outlined in the CDC two Tier Testing algorithm. A copy of the subject's medical record documenting the diagnosis must be obtained, and kept as source documentation at the enrolling site.

Exclusion Criteria:

  • Unable to understand and consent to participation; for minors this includes parent or legal guardian.
Sexes Eligible for Study: All
1 Year and older   (Child, Adult, Senior)
No
Contact: Pamela Benham 858-646-8076 pam.benham@quidel.com
United States
 
 
NCT03238274
CS-0267-01
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No
Plan to Share IPD: No
Plan Description: There is no plan or intention to share participant data with others.
Quidel Corporation
Quidel Corporation
Not Provided
Study Director: Tom Clement Quidel Corporation
Quidel Corporation
August 2017